The 39th David A. Karnofsky lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 445-452

  Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BHQ 880; BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DELANZOMIB; DENDRITIC CELL VACCINE; ELOTUZUMAB; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN; IMMUNOTOXIN CD138DM; LENALIDOMIDE; LUCATUMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 2238; MLN 9708; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5592; MONOCLONAL ANTIBODY DKK1; ONYX 0912; ONYX 912; P 5091; PEPTIDE VACCINE; POMALIDAMIDE; PROTEASOME INHIBITOR; PROTEIN CS 1; PROTEIN KINASE B INHIBITOR; RAP 011; SALINOSPORAMIDE A; SYNDECAN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; X BOX BINDING PROTEIN 1; ZOLEDRONIC ACID;

BONE MARROW; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; DRUG TARGETING; GENOMICS; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84856744110     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.8919     Document Type: Review

References (73)

1. Hideshima T, Mitsiades C, Tonon G, et al: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585-598, 2007 (Pubitemid 47106630)
2. Laubach JP, Richardson PG, Anderson KC: The evolution and impact of therapy in multiple myeloma. Med Oncol 27:S1-S6, 2010 (suppl 1)
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
4. Anderson KC, Pazdur R, Farrell AT: Development of effective new treatments for multiple myeloma. J Clin Oncol 28:7207-7211, 2005
5. Anderson KC, Bates MP, Slaughenhoupt B, et al: Expression of human B cell associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984 (Pubitemid 14120390)
6. Anderson KC, Bates MP, Slaughenhoupt B, et al: A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 32:3172-3179, 1984 (Pubitemid 14104289)
7. Anderson KC, Barut BA, Ritz J, et al: Monoclonal antibody purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 77:712-720, 1991
8. Anderson KC, Anderson J, Soiffer R, et al: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82: 2568-2576, 1993 (Pubitemid 23304284)
9. Belucci R, Alyea E, Chiaretti S, et al: Graft versus tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma cell membrane receptor. Blood 105:3945-3950, 2005 (Pubitemid 40656141)
10. Rabb M, Podar K, Breitreutz I, et al: Recent advances in the biology and treatment of multiple myeloma. Lancet 374:324-339, 2009
11. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364:1046-1060, 2011
12. Tai YT, Anderson KC: Antibody-based therapies in multiple myeloma. Bone Marrow Res [epub ahead of print on March 11, 2011]
13. Tai YT, Dillon M, Song W, et al: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329-1337, 2008
14. Ikeda H, Hideshima T, Fulciniti M, et al: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138- positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028-4037, 2009
15. Vasir B, Borges V, Wu Z, et al: Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Hematol 129:687-700, 2005 (Pubitemid 40825831)
16. Rosenblatt J, Vasir B, Uhl L, et al: Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117:393-402, 2011
17. Bae J, Carrasco R, Lee AH, et al: Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: Potential therapeutic application in multiple myeloma. Leukemia 25:1610-1619, 2011
18. Prabhala RH, Pelluru D, Fulciniti M, et al: Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115:5385-5392, 2010
19. Chauhan D, Singh AV, Brahmandam M, et al: Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 16:309-323, 2009
20. Laubach J, Richardson P, Anderson K: Multiple myeloma. Annu Rev Med 62:249-264, 2011
21. Anderson KC, Carrasco RD: Pathogenesis of myeloma. Annu Rev Pathol 6:249-274, 2011
22. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001 (Pubitemid 32691956)
23. McMillin DW, Delmore J, Weisberg E, et al: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16:483-489
24. Mitsiades N, Mitsiades C, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002 (Pubitemid 35257679)
25. LeBlanc R, Catley L, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000, 2002 (Pubitemid 34984425)
26. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating anti-myeloma activty of proteasome inhibitor PS-341. Blood 101: 1530-1534, 2003 (Pubitemid 36182530)
27. Chauhan D, Hideshima T, Anderson KC: Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol 615:251-260, 2008
28. Mukherjee S, Raje N, Schoonmaker JA, et al: Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504, 2008 (Pubitemid 351206540)
29. Richardson P, Schlossman R, Weller E, et al: The IMiD CC 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002 (Pubitemid 35217050)
30. Richardson P, Blood E, Mitsiades CS, et al: A randomized phase 2 trial of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 15:3458-3464, 2006
31. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
32. Mulligan G, Mitsiades C, Bryant B, et al: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109:3177-3188, 2007 (Pubitemid 46572502)
33. Bianchi G, Oliva L, Cascio P, et al: The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040-3049, 2009
34. Parlati F, Lee SJ, Aujay M, et al: Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114:3439-3447, 2009
35. Zhou HJ, Aujay MA, Bennett MK, et al: Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52:3028-3038, 2009
36. Chauhan D, Singh AV, Aujay M, et al: A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:4906-4915, 2010
37. Chauhan D, Tian Z, Zhou B, et al: In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17:5311- 5321, 2011
38. Chauhan D, Catley L, Li G, et al: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8:407-419, 2005 (Pubitemid 41579835)
39. O'Connor OA, Stewart AK, Vallone M, et al: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15:7085-7091, 2009
40. Singh AV, Bandi M, Aujay MA, et al: PR-924, a selective inhibitor of the immunoproteasome sub-unit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 152:155-163, 2011
41. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
42. Lentzsch S, LeBlanc R, Podar K, et al: Immunodulatory analogs of thalidomide inhibit growth of HS Sultan cells and angiogenesis in vivo. Leukemia 17:41-44, 2003 (Pubitemid 36175886)
43. Görgün G, Calabrese E, Soydan E, et al: Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:3227-3237, 2010
44. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133- 2142, 2007
45. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007 (Pubitemid 350146107)
46. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686, 2010
47. Palumbo A, Bringhen S, Rossi D, et al: Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 28:5101-5109, 2010
48. Palumbo A: First-line treatment of elderly multiple myeloma patients. Clin Adv Hematol Oncol 8:529-530, 2010
49. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 11:29-37, 2010
50. Palumbo A, Falco P, Musto P, et al: Oral revlimid plus melphalan and prednisone for newly diagnosed multiple myeloma. Blood 106:231a, 2005
51. Lacy MQ, Hayman SR, Gertz MA, et al: Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008-5014, 2009
52. Lacy MQ, Hayman SR, Gertz MA, et al: Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24:1934-1939, 2010
53. Breitkreutz I, Raab MS, Vallet S, et al: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932, 2008
54. Raje N, Roodman GD: Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 17:1278-1286, 2011
55. Fulciniti M, Tassone P, Hideshima T, et al: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379, 2009
56. Neri P, Kumar S, Fulciniti MT, et al: Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903-5909, 2007 (Pubitemid 47583918)
57. Orlowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 25:3892-3901, 2007 (Pubitemid 47477266)
58. Chauhan D, Li G, Hideshima T, et al: Hsp27 overcomes Bortezeomib/ proteasome inhibitor PS- 341 resistance in lymphoma cells. Cancer Res 63: 6174-6177, 2003 (Pubitemid 37255160)
59. Hideshima T, Podar K, Chauhan D, et al: p38MAPK inhibition enhances PS-341 (bortezomib)- induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766-8776, 2004 (Pubitemid 39593291)
60. Raje N, Kumar S, Hideshima T, et al: Seliciclib (CYC 202 or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. Blood 106:1042-1047, 2005 (Pubitemid 41076452)
61. Raje N, Hideshima T, Mukherjee S, et al: Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23:961- 970, 2009
62. Ghobrial IM, Weller E, Vij R, et al: Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: A multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 12:263-272, 2011
63. Hideshima T, Catley L, Yasui H, et al: Perifosine, an oral bioactive novel alkyl-lysophospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062, 2006 (Pubitemid 43726814)
64. Catley L, Weisberg E, Kiziltepe T, et al: Aggresome induction by proteasome inhibitor bortezomib and tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108:3441-3449, 2006
65. Hideshima T, Bradner JE, Chauhan D, et al: Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 11:8530-8533, 2005 (Pubitemid 43005896)
66. Hideshima T, Bradner J, Wong J, et al: Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma: Therapeutic implications. Proc Natl Acad Sci U S A 102:8567-8572, 2005 (Pubitemid 40862776)
67. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545, 2004 (Pubitemid 38084672)
68. Mitsiades N, Mitsiades CS, Poulaki V, et al: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 99:4525-4530, 2002 (Pubitemid 34627223)
69. Richardson PG, Weller E, Jagannath S, et al: Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/ refractory multiple myeloma. J Clin Oncol 27:5713- 5719, 2009
70. Munshi N, Hideshima T, Carrasco R, et al: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103:1799-1806, 2004 (Pubitemid 38268976)
71. Carrasco DR, Tonon G, Huang Y, et al: High-resolution genomic profiles defines distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325, 2006
72. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590, 2009
73. Chapman MA, Lawrence MS, Keats JJ, et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011